Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations
4.11.2026 16:00:00 EET | Business Wire | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV).
Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634.
“Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both efficacy and tolerability” said Dr. Andrew Kuykendall, Moffitt Cancer Center and principal investigator of the FM-MF-02 study. “The initial data from the randomized FMF-02 study presented at the ASH meeting last year was very encouraging. The presentation on long-term follow up of this study at this year’s meeting is eagerly awaited. On the FM-MF-02 study, patients with MF and an inadequate response to prior JAKi are randomized to various FM regimens, including both of those (50mg/100mg) reported to be superior to Ruxolitinib in the FMF-02 study, and a third intermediate (75mg) dose. “This study will help define the best FM dosing regimen to take forward in registration studies of FM randomized against approved JAKi for patients with MF. I am very excited about leading it and to working closely with my colleagues on its conduct and generation of key data.”
"It is clear that JAK inhibitors have made a substantial difference in the quality and length of life of patients with MF. It is equally clear that there are significant limitations to the currently approved generation of JAKi” said Raajit Rampal, Director of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center. “Investigation of the biology of MF and of clinical resistance to JAKi in MF has identified several new candidate therapeutic targets in MF/MPN, including cyclin-dependent kinase 6 (CDK6). FM represents a novel drug that combines more specific targeting of JAK2 with CDK6 inhibition. FM-MF-02 is an important milestone study that demonstrates further proof-of-concept that this mechanism-based targeting can extend benefits to patients with MF beyond those observed with a first-generation JAKi such as ruxolitinib. FM is now well-positioned for pivotal registrational studies, and to potentially change currents standards of care."
“There are significant unmet needs for the majority of our patients with MF, the most important of which is the prospect of cure with tolerable therapies. This is a very exciting time for developmental therapeutics in MF as we have agents with diverse modes of action under clinical investigation. I expect JAKi to remain as a cornerstone of MF-therapy and thus the data generated on FM to date is particularly important,” said Claire Harrison, Professor of Myeloproliferative Neoplasms from Guy’s and St Thomas NHS Foundation Trust, and Chair of the FM Scientific Advisory Board. “We need next generation JAKi to further alter the disease course in MF. I found the initial report at to 2025 ASH meeting on the randomized FMF-02 study very intriguing with superiority to Ruxolitinib reported with both FM regimens across a meaningful clinical and molecular spectrum of patients with MF. The conduct of definitive regulatory studies of FM is an urgent necessity, and the FM-MF-02 study is a very important step on that path. Personally, I am very interested in moving rapidly to clinical studies of FM in combination with novel agents with non-JAKi modes of action for patients with MF and in the evolving data on FM for patients with advanced PV which will also be shared at the ASH meeting this year.”
“Our investigator’s satisfaction with the positive data from the prior FMF-02 randomized study of FM versus Ruxolitinib in patients with MF encouraged us to very rapidly advance to the international randomized FM-MF-02 study” said Professor Lijuan Chen, Zenitar Chairman, CEO & CSO. “FM’s clinical success as a highly selective JAK2 inhibitor with unique FLT3 and CDK6 inhibitory activity is very important for patients with MF who need substantial improvements in efficacy over that offered by first generation JAKi. As a FIC clinically important molecule FM validates the AI-driven, structure-based development programs that have generated Zenitar’s broad pipeline. We are excited to again share data on FM with the global community at the ASH meeting. Our expanding rapid conduct of registrational studies is key to getting our agents to patients in need and we are committed to the optimal conduct of these studies with our investigators around the world.”
About Zenitar
Zenitar is a late-stage biopharmaceutical company leveraging AI-driven structural biology to develop and commercialize novel therapeutics for malignant, cardiometabolic, neurodegenerative, and inflammatory diseases. For additional information, please visit the Company’s website at http://en.zenitar.com.cn
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104345488/en/
Contacts
Medical & Clinical Inquiries
CMO: Tomer Mark
tomer.mark@zenitar.cn
+1 (917) 783-4088
Corporate & General Inquiries
Chief of Staff & Head of BD: Neil Wang
neilwang@zenitar.cn
+1 (206) 953-4163
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Unveils Mastering Skin Longevity, a Breakthrough Scientific Innovation Platform Advancing the Next Era of Skin Science6.11.2026 16:00:00 EET | Press release
At the China International Import Expo (CIIE), The Estée Lauder Companies Inc. (NYSE: EL) today unveiled Mastering Skin Longevity, a breakthrough scientific innovation platform designed to advance the next era of skin science and transformative product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106776704/en/ The Estée Lauder Companies' Skin Longevity Clock serves as the visual representation for the Mastering Skin Longevity scientific innovation platform. Moving beyond the study of individual Hallmarks of Aging, the platform focuses further upstream on the Master Regulators of Skin Longevity. These interconnected biological pathways and proteins influence multiple hallmarks at once. By deepening understanding of these systems and how they help support skin’s ability to repair, adapt and regenerate, Mastering Skin Longevity will guide the Company’s discovery across ingredients, technologies, formulations an
IntouchCX Recognized for Operations led AI and End to End CX Transformation by HFS Research6.11.2026 16:00:00 EET | Press release
IntouchCX a global leader in AI-powered customer experience (CX) management, trust and safety, digital engagement, and back-office operations, has been positioned in the Horizon 2 end-to-end experience transformation, in the HFS Horizons Customer Experience Services 2026 report for its operations led approach to AI adoption and its model connecting advisory with delivery, from strategy through frontline executions. HFS Research evaluates customer experience service providers based on their capabilities, innovation, and potential to deliver value. The 2026 report examines how providers are helping businesses adopt AI, improve customer experiences and strengthen operations. “AI transformation delivers the greatest value when strategy, technology, and operations work together,” said Brent Stevenson, Chief Experience Officer at IntouchCX. “Our approach and expertise goes beyond technology. We identify business challenges and build the right solutions by connecting the dots between data, wo
Experian Named a Leader in 2026 IDC MarketScape for Worldwide Decision Intelligence Platforms6.11.2026 16:00:00 EET | Press release
Experian today announced it has been named a Leader in the IDC MarketScape: Worldwide Decision Intelligence Platforms 2026 Vendor Assessment (Doc #US54118426, September 2026), which evaluates providers helping organizations design, engineer and orchestrate increasingly complex decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106302874/en/ IDC MarketScape positions Experian as a Leader in its 2026 vendor assessment of worldwide decision intelligence platform providers. “As organizations embed AI into more consequential decisions, the combination of trusted data, advanced analytics and strong governance becomes increasingly important,” said Keith Little, President of Experian Software Solutions. “Experian brings those capabilities together with decisioning, fraud and identity to help organizations make better decisions with greater speed and confidence.” The Experian Ascend Platform provides a unified analytics and
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 13:04:00 EET | Press release
Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading European producer of uncoated woodfree (UWF) paper for office and commercial printing. Its product portfolio spans cut-size office paper, sold under its own brands such as REY and Multicopy as well as on behalf of major OEM and office supplies customers, and paper reels for commercial printers and converters. Headquartered in Belgium, with two large-scale, vertically integrated pulp and paper mills, it serves a longstandi
Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex6.11.2026 01:23:00 EET | Press release
Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history. Adjusted EBITDA totaled R$5.7 billion in 3Q26, up 9% on the same basis of comparison. Operating cash generation reached R$3.8 billion, an increase of 12%. Net income totaled R$2.1 billion. As announced following the completion of the transaction with Kimberly-Clark, Suzano holds a 51% equity interest in Arbex and will therefore fully consolidate the joint venture’s financial statements from this quarter onwards.1 “This quarter marks the beginning of a new phase for Suzano. With Arbex, we are now a broader business, both ge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom